Unaudited Preliminary Results for the year ended 31 March 2023
Creating a valuable and differentiated Drug Delivery Platform
25 May 2023: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its unaudited preliminary results for the year ended 31 March 2023.